You have no items in your shopping cart.
Search results for: 'Cov'
98.00%
46.7 kDa (predicted)
SARS-CoV-2
A DNA sequence encoding the SARS-CoV-2 Nucleocapsid (YP_009724397.2, with mutations A119S, R203K, G204R, M234I) (Met1-Ala419) was expressed with a polyhistidine tag at the N-terminus. The mutations were identified in the SARS-CoV-2 variant (known as variant P.2) which emerged in the Brazil. Predicted N terminal: Met
N-His
100 μg98.00%
46.6 kDa (predicted)
SARS-CoV-2
A DNA sequence encoding the SARS-CoV-2 Nucleocapsid (YP_009724397.2, with mutations A12G, T205I) (Met1-Ala419) was expressed with a polyhistidine tag at the N-terminus. The mutations were identified in the SARS-CoV-2 variant (known as variant B.1.525) which emerged in the United Kingdom and Nigeria. Predicted N terminal: Met
N-His
100 μg98.00%
46.6 kDa (predicted)
SARS-CoV-2
A DNA sequence encoding the SARS-CoV-2 Nucleocapsid (YP_009724397.2, with mutations R203M, D377Y) (Met1-Ala419) was expressed with a polyhistidine tag at the N-terminus. The mutations were identified in the SARS-CoV-2 variant (known as variant B.1.617/B.1.617.1) which emerged in the India. Predicted N terminal: Met
N-His
100 μg98.00%
26.6 kDa (predicted); 36 kDa (reducing condition, due to glycosylation)
SARS-CoV-2
A DNA sequence encoding the SARS-CoV-2 Spike RBD (YP_009724390.1, with mutations L452R, E484Q) (Arg319-Phe541) was expressed with a polyhistidine tag at the C-terminus. The purified protein was biotinylated in vitro. The mutations were identified in the SARS-CoV-2 variant (known as variant B.1.617) which emerged in the India. Predicted N terminal: Arg 319
C-His
20 μg98.00%
46.6 kDa (predicted)
SARS-CoV-2
A DNA sequence encoding the SARS-CoV-2 Nucleocapsid (YP_009724397.2, with mutation P199L) (Met1-Ala419) was expressed with a polyhistidine tag at the N-terminus. Predicted N terminal: Met
N-His
100 μg98.00%
46.6 kDa (predicted)
SARS-CoV-2
A DNA sequence encoding the SARS-CoV-2 Nucleocapsid (YP_009724397.2, with mutation A220V) (Met1-Ala419) was expressed with a polyhistidine tag at the N-terminus. Predicted N terminal: Met
N-His
100 μg98.00%
46.6 kDa (predicted)
SARS-CoV-2
A DNA sequence encoding the SARS-CoV-2 Nucleocapsid (YP_009724397.2, with mutation M234L) (Met1-Ala419) was expressed with a polyhistidine tag at the N-terminus. Predicted N terminal: Met
N-His
100 μg98.00%
134 kDa (predicted)
SARS-CoV-2
A DNA sequence encoding the SARS-CoV-2 Spike S1+S2 (YP_009724390.1, with mutations D80A, LAL242-244 deletion, R246I, K417N, E484K, N501Y, D614G, A701V) (Met1-Pro1213) was expressed with a polyhistidine tag at the C-terminus. The mutations were identified in the SARS-CoV-2 variant (known as 20C/501Y.V2 or B.1.351 lineage) which emerged in South Africa. Predicted N terminal: Val 16
C-His
100 μg98.00%
76.5 kDa (predicted); 107.9 kDa (reducing condition, due to glycosylation)
SARS-CoV-2
A DNA sequence encoding the SARS-CoV-2 Spike S1 (YP_009724390.1, with mutations E154K, L452R, E484Q, D614G, P681R) (Met1-Arg685) was expressed with a polyhistidine tag at the C-terminus. The mutations were identified in the SARS-CoV-2 variant (known as variant B.1.617) which emerged in the India. Predicted N terminal: Val 16
C-His
100 μg98.00%
132.58 kDa (predicted); 120.5 kDa (reducing conditions)
SARS
A DNA sequence encoding the full-lenght ECD of SARS-CoV (isolate Tor2) spike (NP_828851.1) (Met1-Pro1195) was expressed with a C-terminal polyhistidine tag. The purified protein was biotinylated in vitro. Predicted N terminal: Ser14
C-His
20 μg
